Stockholm Medical Cannabis Conference

The Role of Cannabinoids in SARS-CoV-2 Infection and COVID-19 Management

This article delves into the rapidly growing realm of cannabinoids as potential therapeutic agents in managing COVID-19, engendered by SARS-CoV-2. By navigating through the antiviral and immunomodulatory properties of cannabinoids, the article seeks to provide a nuanced understanding of their potential impact on disease management, while elucidating the pivotal clinical and molecular mechanisms at play. The need for robust clinical trials and further research to corroborate these early insights is emphasized, heralding a call to action for the global scientific community.

Improving cannabinoid posology through nanotechnology

This article explores the role of nanotechnology in improving the delivery and efficacy of cannabinoids. By focusing on nanoencapsulation techniques such as liposomes and polymeric nanoparticles, we delve into how these methods can enhance bioavailability, stability, and therapeutic efficacy of cannabinoids, thereby offering significant advancements in molecular pharmacology.

The Upcoming Unavoidable Divergence of the Medical and Recreational Cannabis Markets

Medical and recreational cannabis markets are likely to diverge further as scientific research reveals more therapeutic benefits of cannabis and its derivatives. This divergence stems from the demand for specific, evidence-based treatments for various medical conditions, which require accurate dosing, controlled formulations, and strict quality standards. On the other hand, recreational cannabis products are mainly designed for consumer satisfaction and preferences, with a wider range of product types and a continuous focus on THC potencies.